Tadalafil Tablet
Product Images NDC 71610-908

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0908 39)

FDA Label Image

Aphena (Aphena)

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This text appears to be describing blood pressure measurements of both diastolic and systolic values in standing and supine positions over time. The readings for Diastolic BP and Systolic BP are given separately for standing and supine positions at different hours. These measurements can be useful for monitoring changes in blood pressure under different postures and through time.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This text appears to show a graph or chart representing the "Standing Systolic BP (Blood Pressure) (mmHg)" levels over some time or treatment. The graph seems to include data points related to "Tadalafil 20 mg & doxazosin 8 mg" at different time intervals. The information presented may be related to the effects of this combination medication on blood pressure.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

This document appears to be a record of Systolic Blood Pressure readings taken at different time points following the administration of different medications (20 mg tadalafil and 8 mg doxazosin). The readings were taken at 08:00 and 20:00. The text presents a comparison between the effects of tadalafil and doxazosin in terms of their impact on blood pressure.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

This text provides information on the IPSS Total Score change from baseline over the duration of treatment with Tadalafil tablets 5 mg compared to a placebo. The graph shows a statistically significant difference (p<0.001) between the two groups over a 12-week treatment period.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

This is a comparison between Tadalafil tablets of 5 mg and a placebo over a duration of treatment in weeks. The results indicate statistical significance with p<0.001.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

LS Mean Change from Baseline for TadalafilFinasteride and PlaceboFinasteride treatment groups. The analysis includes the Least Squares Treatment Difference between the two groups.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text provides information about a study involving Tadalafil tablets at a dose of 5 mg compared to a placebo. The statistical significance is indicated with p<0.01. The outcome of the study is likely related to the duration of treatment in weeks, shown in the graph with time points ranging from 0 to 12 weeks.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.